Bausch + Lomb Corporation (NYSE:BLCO) Given Consensus Rating of “Hold” by Analysts

Shares of Bausch + Lomb Corporation (NYSE:BLCO) have been given an average rating of “Hold” by the fifteen research firms that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $16.3333.

BLCO has been the subject of a number of analyst reports. The Goldman Sachs Group initiated coverage on shares of Bausch + Lomb in a research report on Wednesday, October 1st. They issued a “neutral” rating and a $16.00 price objective for the company. Evercore ISI upped their price objective on shares of Bausch + Lomb from $17.00 to $18.00 and gave the stock an “outperform” rating in a research report on Thursday. Barclays upped their price objective on shares of Bausch + Lomb from $16.00 to $17.00 and gave the stock an “equal weight” rating in a research report on Friday. JPMorgan Chase & Co. upped their price objective on shares of Bausch + Lomb from $13.00 to $16.00 and gave the stock a “neutral” rating in a research report on Thursday. Finally, Morgan Stanley upped their price objective on shares of Bausch + Lomb from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st.

Bausch + Lomb Trading Down 1.3%

NYSE:BLCO opened at $14.94 on Friday. Bausch + Lomb has a 12 month low of $10.45 and a 12 month high of $20.89. The firm has a fifty day simple moving average of $15.00 and a 200-day simple moving average of $13.58. The company has a current ratio of 1.51, a quick ratio of 0.98 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $5.29 billion, a P/E ratio of -17.17, a PEG ratio of 1.71 and a beta of 0.63.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.02. The business had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.28 billion. Bausch + Lomb had a negative net margin of 6.13% and a positive return on equity of 2.42%. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.13 earnings per share. Bausch + Lomb has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Bausch + Lomb will post 0.74 earnings per share for the current year.

Institutional Trading of Bausch + Lomb

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Deutsche Bank AG purchased a new stake in shares of Bausch + Lomb during the first quarter worth about $50,750,000. Alberta Investment Management Corp increased its stake in shares of Bausch + Lomb by 8.6% during the first quarter. Alberta Investment Management Corp now owns 3,266,193 shares of the company’s stock worth $47,360,000 after purchasing an additional 258,000 shares in the last quarter. Goldentree Asset Management LP increased its stake in shares of Bausch + Lomb by 14.9% during the second quarter. Goldentree Asset Management LP now owns 2,583,185 shares of the company’s stock worth $33,524,000 after purchasing an additional 334,916 shares in the last quarter. Oaktree Capital Management LP purchased a new stake in shares of Bausch + Lomb during the second quarter worth about $32,801,000. Finally, Glenview Capital Management LLC increased its stake in shares of Bausch + Lomb by 210.8% during the second quarter. Glenview Capital Management LLC now owns 1,553,855 shares of the company’s stock worth $20,216,000 after purchasing an additional 1,053,855 shares in the last quarter. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.